Ruzaltatug rezetecan clinical trials
How each study uses ruzaltatug rezetecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ruzaltatug rezetecan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
- SHR-A2009
- 5
Studies by the year they started
10 studies that test it; most in 2024 (4)
| Year | Studies |
|---|---|
| 2022 | 3 |
| 2024 | 4 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 7 · Other 3
Suzhou Suncadia Biopharmaceuticals Co., Ltd. (6) · Fudan University (2) · Henan Cancer Hospital (1) · Shandong Suncadia Medicine Co., Ltd. (1)
Often tested with
Tested in the same studies.
Tizetatug rezetecan (3) · Trastuzumab rezetecan (3) · Aumolertinib (2) · Adebrelimab (2) · Notiretatug rezetecan (2) · Famitinib (2) · Bulumtatug fuvedotin (1) · Disitamab vedotin (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 1 in phase 3
Studies that test ruzaltatug rezetecan, phase 3 first.
- Dec 2026A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCPhase 3 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- Dec 2026A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid TumorsPhase 1 · Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Studies
Open first, then newest update. How each study uses ruzaltatug rezetecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- SHR-A2009 Combined With Bevacizumab in the Treatment of Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer : a Randomized Controlled, Open, Multicenter Phase III StudyNot yet recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07895992Written as SHR-A2009 + bevacizumab
- An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer.Not yet recruitingPhase 2Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07863167Written as adebrelimab + SHR-A2009
- Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerRecruitingPhase 2Fudan UniversityNCT06649331Written as SHR-A2009
- Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast CancerRecruitingPhase 1/2Shandong Suncadia Medicine Co., Ltd.NCT06222879Written as HRS-8080; SHR-A2009
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingPhase 2Fudan UniversityNCT05594095Written as SHR-A2009
- Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLCNot yet recruitingPhase 2Henan Cancer HospitalNCT06465238Written as SHR-A2009
- A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLCActive, not recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07183189Written as SHR-A2009 ; Aumolertinib
- A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid TumorsActive, not recruitingPhase 1Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05114759Written as SHR-A2009
- A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLCActive, not recruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT06671379Written as SHR-A2009 monotherapy
- The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid TumorsCompletedPhase 1Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT05394818Written as SHR-A2009
Given beside what is tested · 2 — ruzaltatug rezetecan is usual care or a partner of the new treatment
- A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid TumorsRecruitingPhase 1/2Shanghai Hengrui Pharmaceutical Co., Ltd.NCT06474455Written as SHR-A2009 for Injection
- A Phase Ib Study of HS-10504 Combined Therapy in NSCLCNot yet recruitingPhase 1Jiangsu Hansoh Pharmaceutical Co., Ltd.NCT07414953Written as SHR-A2009
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call ruzaltatug rezetecan · ClinicalTrials.gg INT017732
- UNII (FDA) QZA4R4JG2ZRUZALTATUG REZETECANOne source FDA
- NCI Thesaurus C202278Ruzaltatug RezetecanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | QZA4R4JG2Z | RUZALTATUG REZETECAN | One source FDA |
| NCI Thesaurus | C202278 | Ruzaltatug Rezetecan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.